(Q46627688)

English

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide

scientific article published on 22 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

author name string

M Horowitz

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

T Vilsbøll

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

M Zdravkovic

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

M Hammer

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

publication date

22 April 2008

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

593-596

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00861.X

21 January 2018

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00861.X

21 January 2018

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00861.X

21 January 2018

Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00861.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2008.00861.X

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18435773

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46627688&oldid=2123053021"